Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00041015 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Phase 3 study of Lung Cancer, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 4
- Enrollment target
- 1
- Study location
NCT00041015 is a Phase 3 study of Lung Cancer that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 4 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00041015, a Phase 3 study of Lung Cancer, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective in treating extensive-stage small cell lung cancer. PURPOSE: Randomized phase III trial to compare different chemotherapy regimens in treating patients who have extensive-stage small cell lung cancer.
Conditions Studied
Interventions
- DRUG cisplatin
- DRUG etoposide
- DRUG topotecan hydrochloride
Study Locations (1)
Ohio
- Ireland Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2001-09 |
| Est. Completion | 2002-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00041015
The ClinicalTrials.gov registry entry for NCT00041015 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (100% lower). The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which cisplatin is the first listed.
NCT00041015 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT00041015 about?
NCT00041015 is a clinical study titled "Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective in treating extensive-stage small cell lung can...
What is the current status of trial NCT00041015?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4 participants. The study started on 2001-09. Estimated completion is 2002-11.
What conditions does trial NCT00041015 study?
This clinical trial studies the following conditions: Lung Cancer.
What interventions are being tested in trial NCT00041015?
The interventions under investigation include: cisplatin (DRUG), etoposide (DRUG), topotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00041015?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00041015 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
ACTIVE NOT RECRUITING · Phase 3
-
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
COMPLETED · Phase 3
-
Gemcitabine and Carboplatin Followed By Docetaxel in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.